Following the recent acquisition of USA-based Talecris Biotherapeutics (The Pharma Letter June 2), Spanish drugmaker Grifols (GRLS: MC), has established a new board of directors for its US operations that draws on some of industry's most well-known and experienced leaders, who will assure a smooth integration of the two companies and create a new leader in the plasma therapies market.
This includes the appointment as chairman of the board of Thomas Glanzmann, who previously was president of another leading global plasma therapeutics business, and the reappointment of Gregory Rich as chief executive of Grifols US operations.
Mr Glanzmann was also appointed to direct the integration process because of his past leadership experience in the plasma industry and his history of successfully integrating other companies with plasma product portfolios.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze